Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Galen gets exclusive US rights to Nuvo’s Synera transdermal patch

Executive Summary

Zars Pharma Inc., part of Nuvo Research Inc. (topical pain products and a Phase II compound for immune-related diseases), has licensed Galen US Inc. (the US division of UK-based Galen Ltd.) exclusive US marketing rights to its Synera (lidocaine and tetracaine) transdermal patch, indicated for local dermal analgesia during superficial venous access and superficial dermatological procedures, including excision, electrodessication, and shave biopsy of skin lesions.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
      • Topical Delivery
      • Transdermal
Deal Status
  • Final
Deal Type
  • Alliance
    • Marketing-Licensing
    • Includes Royalty or Profit Split Information

Related Companies

Advertisement
UsernamePublicRestriction

Register